Market closedNon-fractional
Ardelyx/ARDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ardelyx
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Ticker
ARDX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
267
Website
www.ardelyx.com
Ardelyx Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$0.29
EPS
0.82
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
0.82
Financial strength
Current ratio
3.818
Quick ratio
3.344
Long term debt to equity
81.18
Total debt to equity
84.039
Interest coverage (TTM)
-5.66%
Management effectiveness
Return on assets (TTM)
-13.83%
Return on equity (TTM)
-47.64%
Valuation
Price to revenue (TTM)
7.793
Price to book
8.51
Price to tangible book (TTM)
8.51
Price to free cash flow (TTM)
-15.284
Growth
Revenue change (TTM)
152.32%
Earnings per share change (TTM)
-21.61%
3-year revenue growth (CAGR)
130.81%
3-year earnings per share growth (CAGR)
-36.66%
What the Analysts think about Ardelyx
Analyst Ratings
Majority rating from 11 analysts.
Ardelyx Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$46M
34.11%
Net income
-$27M
-7.99%
Profit margin
-57.60%
-31.40%
Ardelyx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
$0.03
-$0.12
-$0.11
-
Expected
-$0.11
-$0.11
-$0.09
-$0.15
-$0.11
Surprise
-30.17%
-128.07%
26.61%
-25.42%
-
Ardelyx News
AllArticlesVideos
Ardelyx sues US health department over kidney disease drug
Reuters·1 week ago
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
GlobeNewsWire·1 week ago
Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ardelyx stock?
Ardelyx (ARDX) has a market cap of $1.3B as of July 27, 2024.
What is the P/E ratio for Ardelyx stock?
The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of July 27, 2024.
Does Ardelyx stock pay dividends?
No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ardelyx dividend payment date?
Ardelyx (ARDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardelyx?
Ardelyx (ARDX) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ardelyx stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.